Healthcare / Medical Instruments & SuppliesShanghai
$8.23
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 10%
FCF escenarios
weak_data · normalized FCF $30.9M · quality 22.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-57.4%
↓Gross Margin
3.9%
↓Debt/Equity
2.56
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.3%
FCF CAGR
—
FCF margin
5.8%
FCF / Net income
-0.34x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $600.5M · net income $-101.7M · FCF $34.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $600.5M | $600.5M | $602.6M | $600.1M | $545.4M |
| Net Income | $-101.7M | $-101.7M | $-190.7M | $-147.4M | $-14.6M |
| EBITDA | $-26.2M | $-26.2M | $-124.0M | $-70.7M | $32.4M |
| EPS | -0.35 | -0.35 | -0.66 | -0.51 | -0.05 |
| Gross Margin | 3.9% | 3.9% | -2.3% | 9.3% | 13.2% |
| Operating Margin | -10.0% | -10.0% | -23.5% | -6.1% | -2.8% |
| Net Margin | -16.9% | -16.9% | -31.6% | -24.6% | -2.7% |
| Balance Sheet | |||||
| Debt/Equity | 2.56 | 2.56 | 1.78 | 1.00 | 0.77 |
| Current Ratio | 0.52 | 0.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $34.5M | $34.5M | $30.9M | $-50.7M | $-114.9M |
| Returns | |||||
| ROE | -57.4% | -57.4% | -68.3% | -31.4% | -2.4% |
| Valuation | |||||
| EV/EBITDA | — | — | — | — | 66.37 |
| P/B | 13.50 | 13.50 | 4.28 | 3.11 | 2.93 |
| Growth & Yield | |||||
| Revenue Growth | -0.3% | -0.3% | 0.4% | 10.0% | — |
| EPS Growth | 47.0% | 47.0% | -29.4% | -920.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+50.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.66 → -0.35
Residual
+50.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.